Nov 20 (Reuters) – Merck said on Friday that its experimental cancer drug helped patients with advanced stomach and esophageal cancers live longer than standard treatment options in a late-stage trial.
Here are some details:
• The trial compared the drug, sacituzumab tirumotecan, also known as sac-TMT, to physician-selected chemotherapy, including trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel
• The trial enrolled 473 patients whose cancer could not be removed by surgery and whose disease had progressed after at least two earlier treatments
• Sac-TMT is an antibody-drug conjugate, a type of targeted cancer therapy designed to deliver cancer-killing drugs directly to tumor cells while minimizing damage to healthy tissue
• Merck said sac-TMT met the trial’s main goal of improving overall survival but did not disclose detailed data, which it plans to present at a future medical meeting
• The study, however, did not meet its secondary goal of delaying cancer progression, as measured by an independent review. Merck said the drug had no new safety concerns
• The results mark another positive late-stage trial for sac-TMT, which Merck licensed from China’s Kelun-Biotech for markets outside Greater China
• Merck is currently testing sac-TMT for multiple cancers, including lung, breast and gastrointestinal tumors
(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Aseem Gujar)

